Acceleron Presents Results of Sotatercept in P-II PULSAR Trial for the Treatment of Pulmonary Arterial Hypertension, Published in NEJM

April 2, 2021 Auto Bot Acceleron, Clinical Trials, Presents, Pulmonary Arterial Hypertension, results, Treatment 0

Shots:

  • The P-II PULSAR trial involves assessing Sotatercept (0.3 mg/kg or 0.3 mg/kg, SC, q3w) vs PBO in 106 patients in a ratio (3:3:4) with PAH. The results were published in NEJM
  • The results of the P-II PULSAR study that demonstrated sotatercept has the potential to provide benefits to patients with PAH on top of currently available therapies. The 1EPs @ 24week trial, showed improvement in pulmonary vascular resistance and 2EPs showed mean improvement from a baseline of six-min walk distance, was well-tolerated
  • The company is planning two additional P-III studies of HYPERION and ZENITH in newly diagnosed patients and with WHO functional class IV disease to treat PAH. Additionally, the P-III STELLAR trial is ongoing

Click here to­ read full press release/ article | Ref: BusinessWire | Image: BusinessWire

The post Acceleron Presents Results of Sotatercept in P-II PULSAR Trial for the Treatment of Pulmonary Arterial Hypertension, Published in NEJM first appeared on PharmaShots.